BRPI1007995A2 - orto-aminoamidas para o tratamento de cãncer. - Google Patents
orto-aminoamidas para o tratamento de cãncer.Info
- Publication number
- BRPI1007995A2 BRPI1007995A2 BRPI1007995A BRPI1007995A BRPI1007995A2 BR PI1007995 A2 BRPI1007995 A2 BR PI1007995A2 BR PI1007995 A BRPI1007995 A BR PI1007995A BR PI1007995 A BRPI1007995 A BR PI1007995A BR PI1007995 A2 BRPI1007995 A2 BR PI1007995A2
- Authority
- BR
- Brazil
- Prior art keywords
- aminoamides
- ortho
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09153445 | 2009-02-23 | ||
EP09157150 | 2009-04-02 | ||
PCT/EP2010/051909 WO2010094678A1 (en) | 2009-02-23 | 2010-02-16 | Novel ortho-aminoamides for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1007995A2 true BRPI1007995A2 (pt) | 2019-09-24 |
Family
ID=42102214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1007995A BRPI1007995A2 (pt) | 2009-02-23 | 2010-02-16 | orto-aminoamidas para o tratamento de cãncer. |
Country Status (14)
Country | Link |
---|---|
US (1) | US7977372B2 (pt) |
EP (1) | EP2398769A1 (pt) |
JP (1) | JP2012518612A (pt) |
KR (1) | KR20110117194A (pt) |
CN (1) | CN102300845A (pt) |
AR (1) | AR075530A1 (pt) |
AU (1) | AU2010215524A1 (pt) |
BR (1) | BRPI1007995A2 (pt) |
CA (1) | CA2751777A1 (pt) |
IL (1) | IL213761A0 (pt) |
MX (1) | MX2011008899A (pt) |
SG (1) | SG173672A1 (pt) |
TW (1) | TW201032800A (pt) |
WO (1) | WO2010094678A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2620027T3 (es) | 2008-09-03 | 2017-06-27 | Biomarin Pharmaceutical Inc. | Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CA2828524C (en) | 2011-02-28 | 2020-01-07 | Repligen Corporation | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
CA2834548C (en) | 2011-04-28 | 2021-06-01 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
WO2014100438A1 (en) | 2012-12-20 | 2014-06-26 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
BR112015023399A8 (pt) | 2013-03-15 | 2019-12-03 | Biomarin Pharm Inc | inibidores de hdac, seu uso e composição farmacêutica |
JP6008201B2 (ja) * | 2013-05-10 | 2016-10-19 | 東レ・ファインケミカル株式会社 | スチレン誘導体の製造方法 |
EA030474B1 (ru) | 2013-11-28 | 2018-08-31 | Киорин Фармасьютикал Ко., Лтд. | Производные мочевины или их фармакологически приемлемые соли |
WO2016094117A1 (en) * | 2014-12-08 | 2016-06-16 | E. I. Du Pont De Nemours And Company | 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones |
EP3737362A1 (en) | 2018-01-12 | 2020-11-18 | Kdac Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
EP3762380B1 (en) | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1033046B (it) | 1970-10-31 | 1979-07-10 | Finotto Martino | Procedimento di fabbricazione di benzimidazoli sostituiti |
DE2201062A1 (de) | 1972-01-11 | 1973-07-26 | Bayer Ag | N-alkoxycarbonyl- bzw. n-alkylthiocarbonyl-2-(2'-thienyl)-benzimidazole, ein verfahren zu ihrer herstellung und ihre verwendung als fungizide |
PT1233958E (pt) | 1999-11-23 | 2011-09-20 | Methylgene Inc | Inibidores de histona desacetilase |
US7208491B2 (en) * | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
JP4809228B2 (ja) * | 2003-09-24 | 2011-11-09 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2559733C (en) * | 2004-03-26 | 2014-05-13 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2008536926A (ja) | 2005-04-20 | 2008-09-11 | メルク エンド カムパニー インコーポレーテッド | ベンゾチオフェン誘導体 |
EP1973405A4 (en) | 2006-01-12 | 2011-06-01 | Merck Sharp & Dohme | HYDROXYALKYLARYLAMID DERIVATIVES |
EP1991226B1 (en) | 2006-02-28 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
US8030344B2 (en) * | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
CN102026969A (zh) * | 2008-05-16 | 2011-04-20 | 霍夫曼-拉罗奇有限公司 | 新型的n-(2-氨基-苯基)-丙烯酰胺类 |
-
2010
- 2010-02-16 CN CN2010800059946A patent/CN102300845A/zh active Pending
- 2010-02-16 EP EP10704145A patent/EP2398769A1/en not_active Withdrawn
- 2010-02-16 KR KR1020117019450A patent/KR20110117194A/ko not_active Abandoned
- 2010-02-16 CA CA2751777A patent/CA2751777A1/en not_active Abandoned
- 2010-02-16 JP JP2011550543A patent/JP2012518612A/ja active Pending
- 2010-02-16 SG SG2011058286A patent/SG173672A1/en unknown
- 2010-02-16 AU AU2010215524A patent/AU2010215524A1/en not_active Abandoned
- 2010-02-16 MX MX2011008899A patent/MX2011008899A/es not_active Application Discontinuation
- 2010-02-16 WO PCT/EP2010/051909 patent/WO2010094678A1/en active Application Filing
- 2010-02-16 BR BRPI1007995A patent/BRPI1007995A2/pt not_active IP Right Cessation
- 2010-02-19 US US12/708,581 patent/US7977372B2/en not_active Expired - Fee Related
- 2010-02-19 AR ARP100100498A patent/AR075530A1/es unknown
- 2010-02-22 TW TW099105046A patent/TW201032800A/zh unknown
-
2011
- 2011-06-23 IL IL213761A patent/IL213761A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010094678A1 (en) | 2010-08-26 |
KR20110117194A (ko) | 2011-10-26 |
SG173672A1 (en) | 2011-09-29 |
MX2011008899A (es) | 2011-09-15 |
TW201032800A (en) | 2010-09-16 |
EP2398769A1 (en) | 2011-12-28 |
CA2751777A1 (en) | 2010-08-26 |
US7977372B2 (en) | 2011-07-12 |
CN102300845A (zh) | 2011-12-28 |
AU2010215524A1 (en) | 2011-06-30 |
IL213761A0 (en) | 2011-07-31 |
AR075530A1 (es) | 2011-04-06 |
JP2012518612A (ja) | 2012-08-16 |
US20100216806A1 (en) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
BR112012005594A2 (pt) | tratamento de câncer | |
BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
SMP200900085B (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative. | |
DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
DK2502172T3 (da) | Hypoglykæmiske behandlingssystemer | |
LT2558105T (lt) | Bardoksolono metilas, skirtas nutukimo gydymui | |
HUE046667T2 (hu) | Rák kombinatív kezelése | |
BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
BRPI1006438A2 (pt) | terapia adjuvante de cancer | |
BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
BRPI1008566A8 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
BR112012002797A2 (pt) | tratamento de câncer de próstata | |
BRPI1008564A2 (pt) | métodos e composições para o dignóstico e tratamento de câncer | |
BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. | |
EP2496244A4 (en) | PHARMACORESISTANT IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | |
BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |